Quest Diagnostics Signals Growth Amid Margin Pressures

Quest Diagnostics ((DGX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Quest Diagnostics’ latest earnings call struck an upbeat tone, underscoring strong organic growth, expanding test volumes and double‑digit gains in full‑year revenue and earnings. Management balanced this optimism with a candid view of near‑term headwinds, including margin dilution from new partnerships, modest pricing pressure per test and lingering regulatory and reimbursement uncertainties.

Broad-Based Revenue Growth

Quest reported fourth‑quarter revenue of $2.81 billion, up 7.1% from a year earlier, with organic revenue rising 6.4%. Management highlighted this as evidence that demand is broad-based across the core business, even after stripping out acquisitions and COVID‑related volatility.

Volume Expansion Outpaces the Market

Total requisitions climbed 8.5% versus 2024, with organic volume up 7.9%. Excluding large new relationships such as Corewell and Fresenius, underlying organic volume still accelerated to 4.1%, signaling healthy utilization gains beyond headline contract wins.

Earnings and Margin Performance

Fourth‑quarter reported EPS reached $2.18, while adjusted EPS rose to $2.42 versus $2.23 last year, an increase of roughly 8.5%. Reported operating income was $386 million, or 13.8% of revenue, with adjusted operating income at $429 million and a 15.3% margin, slightly below last year’s level.

Full-Year Financial Strength

For the full year, Quest delivered double-digit growth in revenue and earnings per share, highlighting durable operating momentum. Cash from operations surged to $1.89 billion in 2025 from $1.33 billion in 2024, a roughly 42% jump that enhances balance sheet flexibility for investment and shareholder returns.

Consumer Channel Gains Traction

The consumer channel generated nearly $250 million in revenue for the year as patients increasingly ordered tests directly. Quest’s questhealth.com platform grew about 35% in 2025, reaching an annual run-rate near $100 million, while consumer-initiated testing volumes exceeded the company’s already strong 20% growth target.

Advanced Diagnostics Drive Mix Upgrade

Advanced diagnostics posted double-digit revenue growth across autoimmune, brain health, oncology and cardiometabolic testing. Key launches included the Analyzer autoimmune platform, the 85‑biomarker Elite Health Profile, a flow MRD test for myeloma and continued adoption of the AD‑Detect Alzheimer’s-related assay.

Productivity and Cost Savings Initiatives

Quest’s INFIGURATE program delivered its full‑year goal of roughly 3% annual cost savings and productivity improvements in 2025. The company credited expanded automation and selective use of AI, including automated sample processing, collaborative accessioning tools and new instrumentation in key laboratories.

AI and Automation Begin to Show Benefits

A virtual AI agent has reduced routine logistics calls by up to 50%, freeing staff for more complex tasks and customer needs. A new AI‑driven logistics tool, slated for broader rollout in 2026, is expected to cut courier transportation times and further streamline operations.

Hospital Partnerships and CoLab Expansion

Management spotlighted CoLab Solutions as a core growth pillar, with the segment expected to approach $1 billion in annual revenue in 2026. The Corewell CoLab relationship alone should contribute about $250 million of organic revenue next year, with a larger joint lab buildout planned to serve Michigan starting in 2027.

Margin Pressure from New Deals and Investments

Adjusted operating margin slipped to 15.3% in Q4 from 15.6% a year earlier, reflecting pressure from low-margin new relationships and upfront investments. The Corewell CoLab revenue is expected to carry low single-digit margins in 2026, improving to the low-teens in 2027, while Project Nova is projected to dilute 2026 EPS by roughly $0.25.

Revenue per Requisition Softens

Total revenue per requisition edged down 0.1% year over year in the fourth quarter, weighed by high-volume but lower-price contracts such as Fresenius and Corewell. While these relationships support strong overall growth, they create a drag on average revenue per test even as total volumes rise.

Weather and Seasonality Risks

Severe weather in January 2026 created a larger disruption than the prior year, temporarily weighing on test volumes and revenue. Management expects partial recovery over the remainder of the quarter but acknowledged that the pacing of this rebound remains uncertain and is already embedded in the full‑year outlook.

Lower Cash Flow Guidance on One-Off Items

Guidance for 2026 operating cash flow, at about $1.75 billion, sits below 2025’s elevated $1.89 billion. The company attributed this to the roll-off of roughly $150 million of one-time cash benefits last year and the impact of one additional payroll cycle in 2026, estimated at about $120 million.

Regulatory Overhang from PAMA

The delay of PAMA implementation to 2026 gives Quest short-term pricing relief but leaves a structural overhang in the U.S. lab reimbursement framework. Management reiterated concerns that historically fewer than 1% of labs have reported data, risking distorted payment rates unless legislative reforms such as the RESULTS Act are adopted.

Oncology Reimbursement Uncertainties

Quest’s oncology pipeline, including Haystack MRD and other advanced assays, is progressing through coding and Medicare processes. However, broader coverage decisions from Medicare Advantage, MolDX and commercial payers remain outstanding, creating reimbursement risk and potential earnings dilution until these tests gain scale.

Integration and Startup Cost Drag

Startup and integration costs tied to the Fresenius Medical Care and Corewell Health relationships pressured operating income in the quarter. Additional spending related to Project Nova and timing of an Epic contract added to near-term expense, though management framed these as necessary investments to underpin future growth and efficiency.

Forward-Looking Guidance and Outlook

For 2026, Quest guided to revenue between $11.70 billion and $11.82 billion, representing 6.0%–7.1% growth, and adjusted EPS of $10.50–$10.70, with operating margin expected to expand. The company plans about $550 million in capital spending and roughly $1.75 billion in operating cash flow, assuming largely flat pricing and steady share count and interest expense versus 2025.

Quest Diagnostics’ earnings call painted a picture of a company leaning into growth while managing through transitional pressures from new contracts, investments and regulatory uncertainty. For investors, the story hinges on whether strong volume trends, consumer and advanced diagnostics traction and productivity gains can more than offset near-term margin and reimbursement headwinds.